PLoS One by Angira, Francis et al.
RESEARCH ARTICLE
Clinical Evaluation of the BD FACSPresto™
Near-Patient CD4 Counter in Kenya
Francis Angira1*, Benta Akoth1, Paul Omolo1, Valarie Opollo1, Scott Bornheimer2,
Kevin Judge2, Henok Tilahun2, Beverly Lu2, Imelda Omana-Zapata2*, Clement Zeh3
1 Kenya Medical Research Institute/US CDCResearch and Public Health Collaboration, Kisumu, Kenya,
2 BD Biosciences, 2350 Qume Drive, San Jose, California, United States of America, 3 US Centers for
Disease Control and Prevention (CDC-Kenya), Kisumu, Kenya
* fangira@kemricdc.org (FA); imelda_omana-zapata@bd.com (IO-Z)
Abstract
Background
The BD FACSPresto™ Near-Patient CD4 Counter was developed to expand HIV/AIDS
management in resource-limited settings. It measures absolute CD4 counts (AbsCD4), per-
cent CD4 (%CD4), and hemoglobin (Hb) from a single drop of capillary or venous blood in
approximately 23 minutes, with throughput of 10 samples per hour. We assessed the perfor-
mance of the BD FACSPresto system, evaluating accuracy, stability, linearity, precision,
and reference intervals using capillary and venous blood at KEMRI/CDC HIV-research lab-
oratory, Kisumu, Kenya, and precision and linearity at BD Biosciences, California, USA.
Methods
For accuracy, venous samples were tested using the BD FACSCalibur™ instrument with
BD Tritest™ CD3/CD4/CD45 reagent, BD Trucount™ tubes, and BD Multiset™ software
for AbsCD4 and %CD4, and the Sysmex™ KX-21N for Hb. Stability studies evaluated dura-
tion of staining (18–120-minute incubation), and effects of venous blood storage <6–24
hours post-draw. A normal cohort was tested for reference intervals. Precision covered mul-
tiple days, operators, and instruments. Linearity required mixing two pools of samples, to
obtain evenly spaced concentrations for AbsCD4, total lymphocytes, and Hb.
Results
AbsCD4 and %CD4 venous/capillary (N = 189/ N = 162) accuracy results gave Deming
regression slopes within 0.97–1.03 and R20.96. For Hb, Deming regression results were
R2 0.94 and slope0.94 for both venous and capillary samples. Stability varied within
10% 2 hours after staining and for venous blood stored less than 24 hours. Reference inter-
vals results showed that gender—but not age—differences were statistically significant
(p<0.05). Precision results had <3.5% coefficient of variation for AbsCD4, %CD4, and Hb,
except for low AbsCD4 samples (<6.8%). Linearity was 42–4,897 cells/μL for AbsCD4,
182–11,704 cells/μL for total lymphocytes, and 2–24 g/dL for Hb.
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Conclusions
The BD FACSPresto system provides accurate, precise clinical results for capillary or




Timely and appropriate initiation of antiretroviral treatment for HIV-positive subjects reduces
morbidity and mortality associated with infections [1, 2]. Moreover, eligibility for antiretroviral
therapy for HIV/AIDS and monitoring progression of the disease commonly have been based
on the number of CD4+ T lymphocytes in a patient’s venous blood [3–7]. Determination of
CD4+ T lymphocytes is usually done at central laboratories, requiring collection and transpor-
tation of the blood from healthcare facilities where patients are referred for HIV care and/or
treatment. Depending on the laboratory capacity, the CD4 results may be available between
2–14 or more days [8] after blood sampling, delaying the start of treatment for newly diagnosed
patients and increasing the risk of loss-to-follow-up [9, 10]. Introduction of point-of-care
CD4+ cell counters can improve access to quick and reliable CD4+ T-cell counts in HIV-posi-
tive patients. Access to care and enabling initiation of treatment during a single clinic visit
increase the efficiency and effectiveness for monitoring and staging of HIV patients [10–14].
Absolute CD4+ cell count (AbsCD4) is a robust surrogate marker for immune competence
in HIV-infected adults. However, percentage of CD4+ cells in the lymphocyte population (%
CD4) has been considered a reliable surrogate marker for children less than 5 years of age,
since the AbsCD4 count varies more than %CD4 due to the lymphocyte development cycle
[15, 16]. Anemia is a hematological abnormality that may result from the use of antiretroviral
treatment (ART) with zidovudine (ZDV) [17] or as a concomitant condition [18]. Anemia has
been defined as a surrogate marker for HIV/AIDS disease progression in pregnant women
[19]. Determination of hemoglobin (Hb) concentration is used as surrogate marker of anemia.
The availability of AbsCD4, %CD4, and Hb concentration from a single blood sample offers an
integrated diagnostic result for more comprehensive management of HIV-infected patients in
resource-limited settings, closer to the patient’s residence, potentially reducing loss-to-follow-
up, promoting initiation of treatment, and improving treatment compliance.
The BD FACSPresto Near-Patient CD4 Counter is a new system containing unit-dose car-
tridges that automatically perform sample preparation from a single drop of venous or capil-
lary blood, and a small and portable instrument that automatically analyzes the sample and
reports AbsCD4, %CD4, and Hb results. The BD FACSPresto™ Cartridge Kit includes the fol-
lowing: the BD FACSPresto™ Cartridge, BDMicrotainer1 Contact-Activated Lancet, sterile
alcohol prep pads, plastic adhesive bandage, sterile non-woven sponge, and transfer pipettes.
The BD FACSPresto Cartridge (“cartridge”) contains dried fluorochrome-conjugated antibody
reagents (CD4 PE-Cy™5/CD3 APC/CD45RA APC/ CD14 PE) and integrated reagent QC,
eliminating the need for refrigeration of reagents. The BD FACSPresto uses fluorescence
microscopy and absorbance spectroscopy to interrogate the cartridge, has embedded software
to analyze the results, and includes integrated instrument quality control. The duration of
the whole process, from blood application onto the cartridge to results, is approximately 23
minutes.
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It is hypothesized that the CD4, %CD4 and Hb results from BD FACSPresto system and
cartridge are accurate, robust, reproducible and linear when using blood within 24 h of draw.
The primary objective of this investigation is to demonstrate the performance of the BD FAC-
SPresto system is similar to the performance of commercially available standard of care instru-
ments and reagents for enumeration of CD4 and Hb using matched venous and capillary blood
specimens from both HIV-positive and HIV-negative subjects. The secondary objective shows
that the BD FACSPresto CD4/ %CD4 and Hb results from venous and capillary blood are
comparable.
Evaluation of the BD FACSPresto system comprised five sub-studies: accuracy, stability,
precision, linearity, and reference intervals, at two sites, the HIV laboratory of the collaboration
between the Kenya Medical Research Institute (KEMRI), and the US Centers for Disease Con-
trol (CDC) in Kisumu, Kenya (KEMRI/CDC), and at BD Biosciences, San Jose, California,
USA. The clinical evaluation of the BD FACSPresto system required specimens prospectively
collected from representative cohorts under care of a healthcare institution in Kisumu, Kenya,
where there is a high prevalence of HIV infections that are diagnosed and monitored using the
BD FACSCalibur™ system, the standard of care or predicate system for CD4. BD Biosciences
completed the FACSPresto linearity and precision analytical studies.
Materials and Methods
At KEMRI/CDC, ethical approval was obtained from the KEMRI/CDC Ethics Review Com-
mittee for evaluation of accuracy and stability protocols in May 12, 2013; amended twice (Sep-
tember 26, 2013 and April 17, 2014) to increase the cohort and include HIV-negative subjects
for the reference intervals protocol. Study subject enrollment started in December 2013 and
was completed by August 2014. The study design, sample size and data analysis procedures
described were derived from the Clinical Laboratory Standards Institute (CLSI) EP09-A2-IR
accuracy and EP24-A2 bias estimation guidelines [20, 21]. The stability study tested the effects
of blood storage and blood staining time on the observed results. Evidence of assay precision
(20-run repeatability, within-run, and total precision), linearity, and normal reference intervals
for AbsCD4, %CD4, and Hb were established in accordance with CLSI guidelines EP05-A2 for
precision [22], EP06-A for linearity [23], and EP28-A3c for reference intervals [24]. The deter-
mination of the patient cohort sample size was based on exceeding by 25% the minimum
enrollment recommended in the CLSI guidelines [21, 24] within the assay range.
Specimens used for the linearity study, executed at BD Biosciences, were procured under
the BD In-House Blood Donor program with the oversight of the Institutional Review Board.
All protocol procedures were conducted under Good Clinical Practices [25] and Good Labora-
tory Practices guidelines to ensure safety and privacy of subjects participating in the study and
compliance with approved protocols.
The testing for accuracy, stability, and reference intervals was carried out at KEMRI/CDC.
Subjects attending to the HIV clinic for CD4 testing were approached, if they were interested
and met the inclusion criteria and none of the exclusion criteria (S1 Table) per protocol.
All subjects provided written informed consent prior to their participation in the study.
Minors (<18 years of age) were distinguished by legal definition between “mature” and “non-
mature.”Mature minors were married, parents, or heads of household, and could consent to
participate in the study as they would do for HIV counseling and testing in Kenya [26], the
KEMRI Ethics Committee approved the method of informed consent used for mature minors.
Non-mature minors required written informed consent from the parents/guardians, followed
by a private discussion with the minors to explain the study, followed by the minors’ written
consent.
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For subjects enrolled in studies at KEMRI/CDC, both venous and capillary blood specimens
were collected from the same subject by trained phlebotomists. Capillary blood collection was
done in accordance with the CLSI H04-A6 document [27], using a BDMicrotainer contact-
activated blue lancet (1.5-mm width x 2.0-mm depth; BD, Franklin Lakes, NJ). One large drop
of capillary blood was transferred directly onto the cartridge to fill the cartridge inlet (~25–
30 μL). Venous blood was collected in tubes with EDTA anticoagulant (BD Vacutainer1 K2,
BD, Franklin Lakes, NJ) and sufficient blood was added to fill the cartridge inlet (~25μL-30 μL)
using the provided transfer pipette. For both capillary and venous specimens, cartridges were
prepared in duplicate and per the manufacturer’s instructions. After blood draw, subjects were
observed to ensure the bleeding through the site of skin puncture during venipuncture or fin-
ger-stick procedures had ceased; the subjects were dismissed concluding their participation
in the study. There were no follow-up visits scheduled and no results from the study were
reported to clinicians. T3he phlebotomists at the sites were blinded to the testing laboratory
procedures, and the laboratory technologists were blinded to the specimen collection and
enrollment procedures.
Precision and linearity testing was conducted at BD Biosciences. For linearity, the venous
blood specimens were procured from the In-House Donor, the donor involvement was limited
to the blood draw procedures. For precision, duplicate control samples were used, and for lin-
earity, triplicate manipulated venous samples were used, as described in more detail as follows.
In each case the samples were transferred directly onto the cartridge using the provided trans-
fer pipette per the manufacturer’s instructions.
The KEMRI/CDC Ethics Committee and BD Biosciences considered the procedures for
venous or capillary blood draw involved minimal risk to the subjects during the evaluation of
an in-vitro device; in addition, the results from the study were delinked from the patient infor-
mation and not reported to the clinicians due to the investigational nature of the BD FAC-
SPresto system, consequently no medical or clinical decisions were derived from the clinical
study results. KEMRI/CDC or BD Biosciences had no requirement for mandatory registration
of the minimal risk clinical studies prior to the subject or specimen enrollment. The authors
confirm that all ongoing Accuracy or Method Comparison testing for this system is registered
in ClinicalTrials.gov. Fig 1 illustrates the studies conducted at KEMRI/CDC and Biosciences.
Accuracy
The accuracy evaluation assessed the equivalency of results between the BD FACSPresto sys-
tem and results obtained using a standard-of-care predicate method for CD4 enumeration (BD
FACSCalibur flow cytometer, BD Tritest CD3/CD4/CD45 reagent with BD Trucount tubes,
and BDMultiset software). The reference system for measurement of Hb concentration was
the Sysmex™ Automated Hematology Analyzer KX-21N (referred as Sysmex KX-21N). Instru-
ments used in the different studies included nine BD FACSPresto systems, two BD FACSCali-
bur systems, and two Sysmex KX-21N hematology analyzers, as well as six different lots of
cartridges.
Venous and capillary blood samples were tested on the BD FACSPresto system, and venous
blood was further tested in duplicate using two reference or predicate methods. The first refer-
ence method was for determination of AbsCD4 and %CD4: BD Tritest CD4/CD45/CD3
reagent in BD Trucount tubes with data acquired on a BD FACSCalibur flow cytometer and
analyzed using BDMultiset software (BD Biosciences, San Jose, CA), operated according to the
manufacturer’s instructions. The second reference method was for determination of Hb con-
centration in venous blood using a Sysmex KX-21N system (Sysmex America, Mundelein, IL),
operated according to the manufacturer’s instructions. Venous blood was tested within 6 hours
BD FACSPresto Clinical Evaluation
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Fig 1. Clinical Evaluation of the BD FACSPresto™Near Patient CD4 Counter Flowchart. The clinical evaluation of
the BD FACSPresto was carried out at KEMRI/CDC and BD Biosciences comprised of the five sub-studies depicted in
the flowchart. KEMRI/CDC evaluated the FACSPresto system using venous and capillary blood specimens from
subjects attending to the clinic for routine visit. Two analytical sub- studies using normal blood and process control
materials were completed at BD Biosciences.
doi:10.1371/journal.pone.0157939.g001
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of collection on BD FACSCalibur and BD FACSPresto systems, and on a Sysmex KX-21N sys-
tem. Capillary blood was always transferred immediately to the cartridge, and both capillary
and venous blood samples were incubated in the cartridges between 18 minutes and 2 hours.
On each day of testing, the BD FACSPresto instrument was turned on, the instrument QC
test was automatically performed, and the results printed. CD4 and Hb external quality con-
trols were run on the corresponding instruments before testing patient samples. BD™Multi-
check low and normal (BD Biosciences, San Jose, CA) quality controls for CD4 were used for
the BD FACSCalibur system. CD Chex™ Plus BC low and normal (Streck, Omaha, NE) quality
controls for CD4 were used for the BD FACSPresto system. Three levels of Hb controls (low,
normal, and high levels) were used in the Sysmex (EIGHTCHECK-3WP-X-TRA Sysmex,
Kobe, Japan). For BD FACSPresto, three levels of Eurotrol 301 (level 1, 2, and 3; Eurotrol B.V.,
Ede, The Netherlands) Hb control were also used. The BD FACSPresto system was used in sev-
eral other sub-studies (described as follows), and the control procedures described were fol-
lowed on a daily basis. In addition, specimens were enrolled by bins to ensure statistical
representation across the assay ranges for each parameter (S1 File). The bins and ranges for
CD4, %CD4, and Hb are shown in Table 1.
Stability
The stability sub-study was designed to evaluate the effects of venous blood storage up to 24
hours after draw using the cartridges or age of blood, and the effects of the time of the stain or
age of stain on both venous and capillary blood at 18 minutes and 2 hours after loading the
blood onto the cartridge. This study was performed exclusively on the BD FACSPresto system.
Venous blood was tested at four different time points (V0, V1, V2, and V3) and capillary blood
at two time points (C0 and C1). Time zero, V0 and C0, were the reference conditions for
“fresh” venous or capillary sample post-draw (testing was performed within 6 hours for venous
or within 2 hours for capillary) and within 30 minutes incubation time in the cartridge for sam-
ple staining, from addition of the blood onto the cartridge to instrument interrogation. Time
points V1 and C1 extended the incubation time to 120 minutes (±15 minutes). Two more time
points for venous blood were studied, time point V2 had between 18 and 30 minutes incuba-
tion time with venous blood 22–24 hours after collection and, time point V3 had 120 minutes
(±15 minutes) incubation time with blood 22–24 hours after collection (S1 File).
Precision
The BD FACSPresto precision evaluation consisted of two studies. The first was a 20-run
repeatability study, and the second consisted of a 21-day evaluation of within-run and total
precision. For the 20-run repeatability study, one operator used one BD FACSPresto instru-
ment and one lot of cartridges to run 20 replicates. In the 21-day precision study, one lot of
process control materials for CD4 (two levels) and one lot of Hb controls (three levels) were
tested by three operators, in three instruments, using three different lots of cartridges, two runs
per day, with a total of 42 runs for the duration of the study.
All precision testing was carried out with commercially available control materials: CD
Chex Plus BC, low and normal levels, and three levels of Eurotrol 301 Hb control. These mate-
rials were used as controls and samples for both studies, the 20-run repeatability and 21-day
precision (S2 File).
Linearity
For linearity testing, normal whole blood specimens were obtained by separating and recom-
bining cell and plasma blood fractions to prepare two sample pools (high and low). Low and
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high pools were mixed to obtain 11 equally spaced concentrations over a range 20%–30%
wider than the anticipated measuring range. While the instrument reports %CD4, estimation
of %CD4 linearity was not included in this analysis. %CD4 is an indirect measurement derived
from the total lymphocyte (Lymphs) and the AbsCD4 cell populations. Linearity for Lymphs
was evaluated (a special software mode was used, since lymph results are not available in the
ordinary BD FACSPresto). Linearity was calculated for AbsCD4, Lymphs, and Hb using one
lot of the cartridges. Each concentration was run in triplicate. Measured results were compared
to the anticipated results per dilution to establish the assay linearity (S3 File).
Reference Intervals
Specimens from enrolled HIV-negative healthy subjects, free of hematological abnormalities
were grouped by age and gender addressing the reference intervals for CD4, %CD4 and Hb
three analytes of the BD FACSPresto cartridge. Venous and capillary blood samples were run
in duplicate within 18–120 minutes incubation time to determine the reference intervals (S1
File).
Table 1. Accuracy Results by Specimen Type and Bins.
Parameter Specimen Type Bins* N Min Max Mean SD Mean%sim %sim SD
AbsCD4 (cells/μL) Venous 50–250 29 55 247 149.1 59.7 102.5 8.6
250–500 59 255 498 380.9 72 99.2 4.7
500–1,000 76 503 997 685.6 147.4 99.3 3.3
1,000–4,000 25 1,020 2,478 1,423.8 393.6 100.1 2.4
Sub-total 189
Capillary 50–250 12 69 242 154.5 60.8 108.7 10.3
250–500 54 262 494 382.1 65.3 102.5 6.7
500–1,000 68 510 998 703.7 137.4 103.8 5.7
1,000–4,000 28 1,003 2,474 1,397.5 459.5 102.7 6.4
Sub-total 162
%CD4 (%) Venous 5–20 53 5.1 19.9 14.7 3.7 100.8 6
20–35 98 20.2 35 27.9 4.4 102.4 3
35–60 36 35.5 53.8 41.5 4.1 101.4 2
Sub-total 187
Capillary 5–20 48 5.9 19.8 14.9 3.6 99.5 4.6
20–35 88 20.2 34.9 27.4 4.5 100.7 3.8
35–60 24 35.1 56.2 40.4 5.1 100.9 2.5
Sub-total 160
Hb (g/dL) Venous 2–9 34 3 8.9 6.7 2.2 100.4 8
9–12 78 9 11.9 10.9 0.7 97.8 1.6
12–17 66 12 16.6 13.7 1.2 98.1 1.5
17–20 6 17.3 18.7 18.1 0.5 99.1 1.5
Sub-total 184
Capillary 2–9 18 4.7 8.9 7.8 1.4 100.8 3.8
9–12 70 9 11.9 10.8 0.8 98.9 2.1
12–17 73 12 16.9 13.7 1.3 99.5 2.5
17–20 1 17.1 17.1 17.1 NA 99.7 NA
Sub-total 162
*Bins based on BD FACSPresto system results. The valid results from first replicate were used to generate the summary statistics.
doi:10.1371/journal.pone.0157939.t001
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Statistical Analysis
Study design and analysis methods are in accordance with CLSI guidelines EP09-A2-IR[21]
and EP24-A2[20] for accuracy, EP05-A2 [22] for precision, EP06-A [23] for linearity, and
C28-A3c [24] for reference intervals. Data collected on Case Report Forms and instrument
files was integrated in the study-specific database. Only evaluable samples were included in the
analysis using statistical software packages (SAS1 v9.3, SAS Institute, Cary, NC; Analyse-it1
v2.22, Analyse-it Software Ltd, Leeds, UK; Microsoft1 Excel1 v12.0, Microsoft, US, and
CBstat5 v5.1.0, US). For accuracy, stability, and reference intervals, the first replicate with valid
results was used for statistical analysis; the second replicate was used as an outlier check to
ensure the quality of the data. Outliers were identified and investigated[21], and no outliers
were removed from analysis.
Accuracy. The venous and capillary results from the BD FACSPresto system were ana-
lyzed independently against the venous results from BD FACSCalibur or Sysmex predicate sys-
tems (S4 File). Agreement of BD FACSPresto venous and capillary and predicate results was
assessed by Deming regression [28] and by Bland-Altman analysis [29] (absolute bias, relative
bias, and limits of agreement). Weighted Deming regression was used to stabilize the variance
in the regression and obtain an accurate estimate of the intercept. The weight adopted in this
analysis was the inversed average squared. [30]. Weighted Deming regression [28, 30] was only
performed on AbsCD4, since the variance increases as the counts increase over a large range.
Ordinary Deming or un-weighted Deming regression was performed on CD4% and Hb since
the values cover a much smaller range and thus can be expected to have relatively similar vari-
ance.[31–33]. Predicted bias intervals from Deming regression were also reported around rec-
ommended cutoffs for AbsCD4 counts[30] of 200, 350, 500, and 750 cells/μL; for %CD4[31] at
15%, 20%, 25%; and Hb[30] at 4, 5, 10.5, and 17 g/dL. In addition, concordance analysis was
performed around these cutoffs, and exact confidence intervals (CIs) were reported using the
Wilson score method [34, 35]. Finally, venous blood and capillary blood Deming regression
analyses for AbsCD4, %CD4, and Hb between were included. Analysis included estimation of
the percentage similarity value (%sim) and standard deviation [21, 36]. A small number of
samples were excluded from analysis due to instrument errors described below.
Stability. The stability study tested the relative bias between samples run at”time zero”
(fresh capillary blood or venous blood<6 hours post-draw and<30 minutes incubation time
in the cartridge) vs later time points of incubation or (venous) blood age. Venous and capillary
blood time points per specimen were analyzed independently. The percent bias between each
study time point and baseline time point (V0 or C0) was calculated for each specimen. Then
the overall percent bias was calculated at each study time point, C1, V1, V2, and V3, across all
the specimens and the data was pooled, yielding the mean percent bias, SD, and the lower and
upper confidence intervals for each time point tested. The 95% CI around the mean bias was
calculated based on the T-distribution (S5 File).
Precision. For the 20-run repeatability study, the standard deviation (SD) and coefficient
of variation (CV) were reported. In the 21-day precision study, within-run and total precision
were calculated for AbsCD4, %CD4, and Hb. Within-run precision means the same operator
runs the same instrument using the same lot of cartridges within a short time period. Variance
for AbsCD4, %CD4, and hemoglobin were estimated by ANOVA, reporting the SD(s) and per-
cent of coefficient of variation (%CV) with the upper 95% CI for within-run and total preci-
sion. Data from 42 runs (2 runs per day during 21 days) with duplicate values were included in
the analysis. Precision for AbsCD4, %CD4, and Hb concentration was analyzed separately.
Linearity. Weighted polynomial regression models (1st order, 2nd order, and 3rd order)
were fitted to the measured results as a function of the expected values or coded levels for each
BD FACSPresto Clinical Evaluation
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of the variables: a) AbsCD4, b) total Lymphs, and c) Hb. All results from triplicate cartridges
were used in the regression analysis. The coefficients for the nonlinear terms (2nd order and 3rd
order terms) of the higher order models were tested to determine statistical significance. If the
higher order coefficient differences were not statistically significant, then the data was deemed
linear with no further analysis required. If the higher order coefficients were statistically signifi-
cant, then the degree of non-linearity was studied by taking the difference between the best
higher order fit and the 1st order linear fit at each concentration level. If the difference was
within the acceptance criteria for each level, then the data was adequately linear[23]. The
pooled data across the different concentration levels was reported to ensure good fit (S6 File).
Reference Intervals
Reference intervals were analyzed in venous (N = 151) and capillary (N = 150) blood specimens
using only the first replicate measurement and calculating the 2.5 and 97.5 percentiles of the
observed measurement range for AbsCD4, %CD4, and Hb per specimen type, gender and age.
Differences by age and gender were tested for statistical significance (S7 File).
Results
Demographic Information
The total number of HIV+ enrolled subjects included 241 (179 in accuracy and 62 in stability
studies) from KEMRI/CDC. An additional 21 HIV+ venous blood specimens were procured
from an external vendor for sample manipulation to fill the accuracy bins at BD; and HIV-neg-
ative subjects free of hematological abnormalities were also enrolled (N = 155), 152 in the refer-
ence interval study at KEMRI/CDC, and 3 in the linearity studies (Fig 1).
The median age of the adolescent/adult population was 36 years (range, 18–77 years), and
for children the median age was 8 years (range 2–17 years) in the accuracy and stability studies;
by gender, 64% were females (N = 154), and 36% were male subjects (n = 87). During enroll-
ment, patient verbally reported co-morbid conditions, including anemia (2%); malaria (4.5%),
tuberculosis (2%), diabetes mellitus (1.6%), and high blood pressure (1.7%). Enrolled subjects
reported taking medications that included antiretroviral drugs (79%), and Septrin or Dapson
as prophylaxis (95%). The right hand was more frequently used (62%) for capillary blood
collection.
Accuracy
Specimens tested according to the protocol requirements that provided valid results were
included in analysis and grouped in predefined bins for AbsCD4, %CD4, and Hb parameters
based on the analytical range of the assay. The number of specimens with valid results included
in the analysis varied by specimen type venous/capillary (N = 189/N = 162) and parameter:
AbsCD4 (187/160), %CD4 (184/162), and Hb (190/163). All capillary blood specimens had a
corresponding venous sample from the same subject. The descriptive statistics for AbsCD4
count, %CD4, and Hb measured values are illustrated in Table 1. This table also includes the
mean percent similarity (%sim) and %sim standard deviation (SD) results per bin. Eleven spec-
imens were completely excluded form analysis; the reasons for exclusion were the following:
the process controls were not acquired prior to acquiring patient data, results were outside the
validated claim range or suppressed by the instrument or one replicate was missing.
The Bland-Altman bias results for venous AbsCD4 and %CD4 showed a mean percent bias
with 95% limits of agreement (LoA) for AbsCD4 of -0.78 (-21.26; 19.69) cells/μL and %CD4 of
3.19 (-14.01; 20.40); for capillary blood was 6.1 (-17.34; 29.55) cells/μL AbsCD4 and for %CD4,
BD FACSPresto Clinical Evaluation
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the mean bias was 0.41 (-15.36;16.18). For Hb, the Bland-Altman Hb bias analysis with 95%
LoA for venous blood was -3.53 (-20.48; 13.42) g/dL, and for capillary blood was -1.31 (-11.49;
8.86) g/dL) as illustrated in the Bland-Altman plots Fig 2.
Table 2 summarizes the results from three analyses, mean bias by Deming Regression and
Bland-Altman and mean %sim with the lower and upper limits. Notice the Bland-Altman
mean %bias is reported with 95% limits of agreement (LoA), whereas the mean %bias and the
mean %sim are reported with 95% confidence intervals (95% CI). The valid results from first
replicate were used to generate the summary statistics.
In addition, the linear Deming regression results for each parameter in venous or capillary
blood are depicted as R2, slope and intercept in Table 3. The Deming regression graphs (S1
Fig) can be found in Supplement section.
The predicted bias from Deming regression with 95% CI at candidate decision points of
200, 350, 500 and 700 cells/μL, as well as for 15, 20 and 25% for %CD4 are reported (Table 4).
In addition, the two-by-two (2x2) concordant table with the overall, positive and negative
agreements for AbsCD4 in venous blood at 350 cells/μL are shown in Table 5.
The concordance analysis for additional decision points is summarized (Table 6) as overall
agreement with 95% CI and positive percent and negative percent agreement.
The regression analysis for equivalency between venous and capillary blood results provided
R2  93.5% (Fig 3).
Stability
Only specimens tested under protocol procedures that provided valid results were included in
the analysis. The study included 24 manipulated venous blood specimens to assess the high
end of the linear range of the assay. Eight specimens with at least one parameter with valid
results were included in the statistical analysis, two specimens were completely excluded due
missing the time zero results. Stability descriptive statistics results by parameter bin and speci-
men type are summarize in Table 7.
The AbsCD4 cells/μL mean (range) at time zero (V0/C0) was 609.24 (54–1,969) for venous
blood and 666 (61–2,461) for capillary blood. The %CD4 mean (range) in venous blood was
26.7% (5.1%–54.8%) and 26.9% (5.3%–55.8%) for capillary blood. Hb concentration in g/dL
showed a mean (range) of 11.9 (4.8–19.1) in venous blood and 11.5 (4.5–16.3) in capillary
blood.
The mean percent biases across all stability conditions were within 6.2% for CD4, 9.3% for
%CD4, and 2.1% for Hb (Table 8). Results are presented per specimen type (V or C) and time
point (1, 2 or 3). Each time point is comprised by the age of the blood (0h or 22h), and the
duration of the incubation of the cartridge (0h or 2h).
Precision
The 20-run repeatability results (Table 9), for low CD4 samples the %CV was within 5.8%, and
for normal CD4 samples was within 2.6%, for CD4, %CD4, and Hb (data will be provided
upon request).
The results of the 21-day precision study (Table 10a and 10b) showed the %CV for AbsCD4
and %CD4 within 6.8% for low samples and 3.4% for normal samples; and the %CV for the
three levels of Hb was within 2.4% (Table 10c).
Linearity
The analytical range of the assay was determined by the linear relationship between the expected
and the measured ranges for each parameter. The determined linear range for AbsCD4 was
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Fig 2. Bland-Altman Plots for AbsCD4, %CD4 and Hb in Venous and Capillary Blood. Bias results are illustrated in the Bland-
Altman plots with limits of agreement for venous blood (2A, 2C and 2E) on the left side and for capillary blood (2B, 2D and 2F) on the
right side. Biases for AbsCD4 are show in 2A and 2B; for %CD4 in 2C and 2D and hemoglobin in 2E and 2F. The x-axis displays the
average (AbsCD4, %CD4 or Hb) and the y-axis is the difference (AbsCD4, %CD4 or Hb).
doi:10.1371/journal.pone.0157939.g002
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42–4,897 cells/μL, for total Lymphs, 182–11,704 cells/μL, and for Hb, 2–24 g/dL, with R2 = 0.99
for all. The %CVs the different concentration levels were pooled using the root mean square
method and all the %CVs values were4.6%. Results are summarized in Table 11.
Reference Intervals
The median age for normal subjects was 29 years (range, 13–65 years). Age difference results
were not statistically significant when comparing groups of 13 to<18, 18 to<30, 30 to<42,
Table 2. Deming Regression, Bland-Altman Mean Bias andMean Percent Similarity Results Comparison with Limits of Agreement.








189 -0.28(-1.46;0.91) -0.78(-21.26;19.69) 99.86(99.27;100.45)
%CD4 (%) 187 3.6(2.63;4.56) 3.19(-14.01;20.40) 101.80(101.32;102.28)
Hb (g/dL) 184 -3.16(-4.08;-2.23) -3.53(-20.48;13.42) 98.42(97.96;98.88)
Capillary AbsCD4
(cells/μL)
162 7.11(5.37;8.86) 6.1(-17.34; 29.55) 103.56(102.68;104.43)
%CD4 (%) 160 0.72(-0.3;1.74) 0.41(-15.36;16.18) 100.36(99.85;100.87)
Hb (g/dL) 162 -1.17(-1.85;-0.5) -1.31(-11.49;8.86) 99.41(99.08;99.85)
doi:10.1371/journal.pone.0157939.t002
Table 3. Summary of the Deming Regression Results.
Specimen Parameter R2 Slope (CI) Intercept (CI)
Venous CD4 (cells/μL) 0.98 0.97 (0.95,0.99) 7.37 (-0.03,14.76)
%CD4 (%) 0.96 1.03 (1.00,1.05) 0.13 (-0.55,0.85)
Hb (g/dL) 0.96 0.94 (0.91,0.98) 0.18 (-0.27,0.64)
Capillary CD4 (cells/μL) 0.97 1.03 (0.99,1.07) 13.47 (-1.91,28.85)
%CD4 (%) 0.96 1.02 (0.99,1.05) -0.26 (-1.03,0.49)
Hb (g/dL) 0.94 0.98 (0.94,1.02) 0.08 (-0.41,0.55)
doi:10.1371/journal.pone.0157939.t003
Table 4. Deming Regression Predicted Accuracy Interval at Different Cutoffs.
Type Parameter Decision Level Bias (with 95% CI) Percent (%) Bias (with 95% CI)
Venous CD4 (cells/μL) 200 1.7 (-3.8, 7.2) 0.85 (-1.9, 3.6)
350 -2.5 (-7.7, 2.7) -0.71 (-2.2, 0.77)
500 -6.8 (-12.8, -0.7) -1.36 (-2.56, -0.14)
750 -13.8(-22.9, -4.8) -1.84(-3.05, -0.64)
%CD4 (%) 15% 0.55 (0.16, 0.94) 3.67 (1.07, 6.27)
20% 0.69 (0.37, 1.01) 3.45 (1.85, 5.05)
25% 0.83 (0.55, 1.11) 3.32 (2.20, 4.44)
Hb (g/dL) 4.5 -0.07 (-0.36, 0.22) -1.56 (-8.00, 4.89)
10.5 -0.40 (-0.52, -0.27) -3.81 (-4.95, -2.57)
17 -0.76 (-0.89, -0.62) -4.47 (-5.24, -3.65)
Capillary CD4 (cells/μL) 200 19.6 (9.9, 29.4) 9.8 (4.95,14.7)
350 24.3 (16.5, 32.0) 6.94 (4.71, 9.14)
500 28.9 (19.5, 38.2) 5.78 (3.90, 7.64)
%CD4 (%) 15% 36.6(20.2, 53.0) 4.9(2.7, 7.1)
20% -0.01 (-0.38, 0.36) -0.07 (-2.53, 2.4)
25% 0.07 (-0.22, 0.37) 0.35 (-1.10, 1.85)
doi:10.1371/journal.pone.0157939.t004
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42 to<54, and 54 to65 years; however gender differences were statistically significant
(p<0.01). Reference intervals per parameter, specimen type and gender are summarized in
Table 12. One female subject was excluded due to age outside the range and results from sec-
ond capillary specimen were suppressed (CD4 and %CD4), including only Hb results in the
analysis.
Cartridge Failure and Error Rate
During acquisition, if there was an error with an instrument error code, the site staff typically
re-ran the cartridges. A cartridge failure was considered as an unsuccessful attempt to generate
results after a second acquisition of the same cartridge. This required re-preparing the sample
using a new cartridge. There were 2,875 cartridge runs during the accuracy, stability, and
Table 5. Venous AbsCD4 Comparison between BD FACSPresto and BD FACSCalibur Systems at Cutoff of 350 cells/μL.
Agreement BD FACSCalibur
Positive Negative Total
BD FACSPresto Positive 44 2 46
Negative 6 137 143
Total 50 139 189
Overall Agreement** = (44+137)/189*100% = 95.8%
Positive Agreement*** = (44/50)* 100% = 88.0%
Negative Agreement& = (137/139)*100% = 98.6%
**Overall agreement is defined as the proportion of subjects in whom the new test and the non-reference standard give the same outcome.
***Positive agreement refers to the proportion of non-reference standard positive subjects in whom the new test is positive or cutoff.
&Negative agreement is defined as the proportion of non-reference standard negative subjects in whom the new test is negative or >cutoff.
doi:10.1371/journal.pone.0157939.t005
Table 6. BD FACSPresto and BD FACSCalibur Agreement at Different Cutoffs.
Parameter Type Agreement at Cutoffs 200 350 500 750
AbsCD4 (cells/μL) Venous Overall 99.5% 95.8% 96.3% 99.5%
95% CI# (LL/ UL) 97.1/ 99.9% 91.9/ 97.8% 92.6/ 98.2% 97.1/ 99.9%
Positive Percent Agreement 100.0% 88.0% 93.2% 100.0%
Negative Percent Agreement 99.4% 98.6% 99.0% 98.0%
Capillary Overall 98.80% 94.40% 95.1% 95.1%
95% CI# (LL/ UL) 95.6/ 99.7% 89.8/ 97.1% 90.6/ 97.5% 90.6 97.5%
Positive Percent Agreement 100.00% 87.10% 93.9% 100.0%
Negative Percent Agreement 98.7% 96.2% 95.8% 84.3%
Parameter Type Agreement at Cutoffs 25%
%CD4 (%) Venous Overall 93.1%
95% CI# (LL/ UL) 88.5/ 95.9%
Positive Percent Agreement 96.3%
Negative Percent Agreement 90.7%
Capillary Overall 90.1%
95% CI# (LL/ UL) 84.5/ 93.8%
Positive Percent Agreement 88.8%
Negative Percent Agreement 91.4%
#CI of the overall agreements was calculated based on the Wilson Score Method.
doi:10.1371/journal.pone.0157939.t006
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reference interval testing, with a total of 55 cartridge failures. Fifty-four were sample replicates,
and one error was for Hb control.
The overall error rate was 1.9% for accuracy, stability, and reference interval testing, the car-
tridge or instrument errors suppressed results from one parameter but reported results from
other parameter, for example Hb. The error codes observed during testing were: 6B0F (n = 34),
6B0D (n = 19), 6B0E (n = 1), and 6B07 (n = 1). The error code 6B0F occurred most often in
samples with blood stored22 hours post draw and can be related to diminished cell signal.
The error code 6B0D is associated with non-homogenous distribution of the blood sample in
the cartridge channel, which could have been related to inappropriate blood transfer or
Fig 3. Comparison of Venous and Capillary Blood on the BD FACSPresto. Comparison of venous and capillary Deming regression results are shown
for AbsCD4 (A), %CD4 (B), and Hb (C) with R2 (%), intercept, and slope.
doi:10.1371/journal.pone.0157939.g003
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Table 7. Time Zero Stability Results Summary by Specimen Type and Bins.
Parameter Specimen Type Bins N Min Max Mean SD
AbsCD4 (cells/μL) Venous 50–250 7 54 238 158.3 67.9
250–500 17 252 491 383.9 83.2
500–1,000 30 510 976 704.1 149.6
1,000–4,000 4 1,191 1,969 1,644.8 326.3
Sub-total 58
Capillary 50–250 4 61 171 122 52.4
250–500 12 265 462 366.3 64.1
500–1,000 25 505 994 712.6 144.9
1,000–4,000 6 1,049 2,461 1,433.7 540
Sub-total 47
%CD4 Venous 5–20 17 5.1 19.9 13.6 5.2
20–35 29 20.7 33.5 27.6 3.8
35–60 14 35.9 54.8 40.9 5.2
Sub-total 60
Capillary 5–20 13 5.3 19.7 14 4.6
20–35 22 20.3 33.9 27.8 4.1
35–60 11 35.6 55.8 40.1 5.8
Sub-total 46
Hb (g/dL) Venous 2–9 11 4.8 8.7 7.3 1.2
9–12 14 9 11.5 10.5 0.9
12–17 26 12 15.4 13.4 0.9
17–20 5 17.8 19.1 18.2 0.5
Sub-total 56
Capillary 2–9 11 4.5 8.9 7.5 1.3
9–12 14 9.4 11.9 10.8 0.9
12–17 23 12.1 16.3 13.9 1.1
17–20 0 NA NA NA NA
Sub-total 47
doi:10.1371/journal.pone.0157939.t007
Table 8. Venous and Capillary Blood Stability Results.
Specimen Type Parameter Time point (h/h) N Mean%Bias^ SD 95% Low CI 95% Upper CI
Venous AbsCD4 (cells/ μL) V1 (0/2) 57 3.40 7.82 1.67 5.13
V2 (22/0) 53 1.36 14.30 -1.93 4.65
V3 (22/2) 54 6.17 12.24 3.38 8.96
%CD4 V1 (0/2) 59 3.93 11.16 1.50 6.35
V2 (22/0) 54 4.32 11.78 1.64 7.00
V3 (22/2) 55 9.21 12.44 6.41 12.02
Hb (g/dL) V1 (0/2) 55 2.06 3.75 1.21 2.90
V2 (22/0) 52 0.33 3.96 -0.59 1.25
V3 (22/2) 54 1.88 4.66 0.82 2.94
Capillary AbsCD4 (cells/ μL) C1 (0/2) 46 1.49 10.38 -1.08 4.06
%CD4 C1 (0/2) 44 5.55 7.82 3.56 7.53
Hb (g/dL) C1 (0/2) 47 1.52 5.44 0.19 2.86
^Mean %Bias is calculated with respect to a time point zero reference (V0 or C0).
doi:10.1371/journal.pone.0157939.t008
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incubation. The error 6B0E is related to unexpected cell distribution, and error 6B07 refers to
insufficient quality images for the Hb analysis.
Protocol Deviations
There were a total of four minor protocol deviations, for accuracy the FACSCalibur settings for
the minimum lymphocyte events did not follow the protocol, in addition, two capillary samples
were acquired before running the process controls. In stability, samples with two different time
points from the same specimen type were acquired using different FACSPresto instruments.
Table 9. Precision Results—Twenty-run Repeatability.
Parameter Sample Mean N SD SD—95% Upper CI %CV CV- 95% Upper CI
AbsCD4 (cells/ μL) Low 155.1 20 8.97 12.29 5.78 7.37
Normal 926.6 20 24.04 32.95 2.59 3.3
%CD4 (%) Low 12.77 20 0.73 1.01 5.74 7.32
Normal 43.99 20 0.67 0.92 1.53 1.95
Hb (g/dL) Low 6.95 20 0.16 0.22 2.26 2.88
Normal 12.99 20 0.14 0.19 1.09 1.38
doi:10.1371/journal.pone.0157939.t009
Table 10. Precision Results—Within-run and Total Precision.
Parameter Sample Precision Mean DF SD SD—95% Upper CI %CV %CV—95% Upper CI
AbsCD4 Low Within Run 155.96 42 10.6 12.95 6.79 8.03
Total 155.96 83 10.6 12.16 6.79 7.67
Normal Within Run 940.93 42 20.55 25.1 2.18 2.58
Total 940.93 83 31.02 35.61 3.3 3.72
%CD4 Low Within Run 12.55 42 0.75 0.92 5.98 7.07
Total 12.55 83 0.75 0.86 5.98 6.75
Normal Within Run 43.9 42 0.69 0.85 1.58 1.87
Total 43.9 83 0.76 0.88 1.74 1.96
Hb (g/dL) Level 1 Within Run 6.9 42 0.17 0.2 2.42 2.86
Total 6.9 83 0.17 0.19 2.42 2.73
Level 2 Within Run 12.74 42 0.19 0.23 1.46 1.72
Total 12.74 83 0.19 0.22 1.52 1.72
Level 3 Within Run 16.87 42 0.18 0.22 1.07 1.27
Total 16.87 83 0.19 0.22 1.14 1.28
DF = degrees of freedom, refers to the number of independent values. In the precision study, the total tubes collected were 21 (days) x 2 (runs) x 2
(replicates). Therefore, the total degree of freedom is 84–1 = 83. Within-run degrees of freedom are 21 (days) x 2 (runs) = 42.
SD = standard deviation.
%CV = percent coefficient of variation.
doi:10.1371/journal.pone.0157939.t010
Table 11. Linearity Range.
Parameter Overall %CV! R2 Final Range Product Claim Range
AbsCD4 (cells/μL) 4.36 0.997 42–4,897 50–4,000
Total Lymphs (cells/μL) 2.55 0.999 182–11,704 20–10,000
Hb (g/dL) 4.60 0.999 2–24 2–20
!Overall %CV = the mean of the %CV across all the triplicate measurements at each linearity interval.
doi:10.1371/journal.pone.0157939.t011
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For linearity, a low level sample did not followed the predefine order during acquisition. The
protocol deviations were minor and had minimum impact on the quality of the data.
Discussion and Conclusions
This is the first evaluation of the performance of the BD FACSPresto Near-Patient CD4
Counter after its introduction in the market with the intent of increasing access to CD4 testing
and services in resource-limited settings. The BD FACSPresto Near-Patient CD4 Counter,
along with other point-of-care devices, enables the collection and testing of samples in the local
community and overcomes time or geographical constraints. The system is a response to the
UNMillennium Development Goals to improve maternal health, child health, and combat
HIV/AIDS in developing countries [37]. The point-of-care CD4+ cell counter(s) currently on
the market use venous and capillary blood [13, 14, 38, 39] to enumerate CD4 absolute count in
human whole blood.
AbsCD4 is a widely accepted surrogate marker for the decision to start ART in adolescent
and adult patients. For children under 5 years of age, results from %CD4 are considered a more
reliable surrogate marker due to normal lymphocytosis at that age range [15]. The BD FAC-
SPresto system provides results for both AbsCD4 (cells/μL) and %CD4 of a T-cell lymphocyte
population. These parameters are used for monitoring HIV-infected populations that have no
access to viral load monitoring and are also used for monitoring children and subjects with co-
infections, opportunistic infections, or treatment failure [40, 41]. Determination of CD4 cell
count is relevant for rapid monitoring of these subjects in their community using CD4-point-
of-care devices. The BD FACSPresto Near-Patient CD4 Counter also includes a third analytic
parameter, measurement of the concentration of Hb (g/dL or g/L) from the same sample,
which is an important marker for anemia as a prognostic factor in HIV infection (Fig 2 and
S1 Fig).
Anemia is a commonly encountered hematological abnormality that has a significant
impact on clinical outcomes of the patients [17, 19]. ZDV is known for hematological adverse
effects that include anemia, neutropenia, and macrocytosis [17, 42]. Determination of the con-
centration of Hb may be an indicator for early detection of anemia in patients receiving ART
combination therapy that includes ZDV [42], and for monitoring of HIV-infected pregnant
women and children. Several studies have shown that Hb concentration reflects the rapidity of
disease progression rates and independently predicts prognosis across demographically diverse
populations [18, 19]. The rate at which Hb decreases also correlates with falling CD4 counts
Table 12. Reference Intervals Partitioned by Gender.
Blood Type Subset Gender N Mean Reference Interval
CD4 Male 76 881 469–1,437
(cells/μL) Female 75 1,054 503–1,679
Venous %CD4 Male 76 39.99 29.15–52.54
(%) Female 75 42.95 30.66–54.67
Hb Male 76 14.17 10.9–16.8
(g/dL) Female 75 12.2 8.2–15
CD4 Male 76 930 510–1,552
(cells/μL) Female 74 1,122 508–1,851
Capillary %CD4 Male 76 37.92 26.86–49.39
(%) Female 74 41.37 30.56–53.16
Hb Male 76 14.56 11.2–17.5
(g/dL) Female 75 12.48 8.5–14.7
doi:10.1371/journal.pone.0157939.t012
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[43], suggesting that increases in Hb are predictive of treatment success [44, 45]. Integration of
these three parameters in the BD FACSPresto Near-Patient CD4 Counter is intended for more
integrated and comprehensive routine monitoring of HIV/AIDS patients in resource-limited
settings using capillary blood.
Schalk et al [46] reported differences in Hb and hematocrit capillary measurements. How-
ever, Daae et al found equivalency of the cellular components between venous and capillary
blood [47]. Recently, it was reported that CD4 results were comparable to the predicate when
the cartridges were filled using a pipette, but not for capillary blood transfer [48]. A study by
Sitoe et al [49] showed that venous and capillary blood enumeration of both CD4+ T-cell abso-
lute count and %CD4 using the BD FACSCalibur and BD FACSCount™ systems was similar.
The FACSPresto mean bias results in Tables 2 and 3, Fig 2 and S1 Fig lead to similar conclu-
sions, the numeric values of the mean bias and Bland-Altman mean bias are closer. In addition,
the mean %sim for AbsCD4, %CD4 and Hb showed the close agreement of the FACSPresto
with the predicate methods in venous and capillary blood results (Fig 2 and S1 Fig), demon-
strating equivalency for CD4 determination. The challenge with CD4 determination in capil-
lary blood is that the sample must be whole blood to provide valid results (Fig 3). Therefore,
validation of the capillary blood collection method, the device selected for finger-stick, and the
steps to efficiently transfer the drop of blood onto the cartridge are fundamentally important to
obtain accurate results (Fig 2). The capillary blood collection method used with the patients
participating in the studies was a reproducible and robust method, since our results from these
two specimen types were equivalent as shown in the results from the accuracy (Fig 3), stability
and reference interval studies.
The clinically relevant AbsCD4 cutoff in venous blood of 350 cells/μL was used to analyze
overall positive or negative agreement. The BD FACSPresto overall agreement for AbsCD4 was
95.8%; positive agreement was 88.0%, and negative agreement was 98.6% (Table 5). Analyses at
different AbsCD4 cutoffs (Table 6) provide additional information showing that the BD FAC-
SPresto’s overall agreement for identifying patients eligible for treatment in both venous and
capillary blood was94.4%, and for %CD4 was90.1%. Negative agreement for AbsCD4 was
95.8% for all cutoffs with exception of capillary blood at the 750 cells/μL cutoff. For %CD4,
the positive agreement was88.8% and the negative agreement was90.7% for both venous
and capillary blood. These results show acceptable agreement of the BD FACSPresto system
with the AbsCD4 predicate FACSCalibur/BD Tritest method. However, at a cutoff of 200 cells/
μL, the number of subjects was small. Therefore, additional studies would be required to
address misclassification at this clinically relevant cutoff frequently used for monitoring sub-
jects with co-infections or opportunistic infections [40, 41]. Other authors have used similar
analyses presented as sensitivity and specificity for other point-of-care products in the market
[13, 14, 16, 38, 39, 50].
The results from Hb concentration in venous blood show the concentration of Hb in Bland-
Altman plots (Fig 2E and 2F). Although most of patient data fell within the normal ranges, the
graph also depicts results with larger variability either below 8 or above 17 g/dL. These results
correspond to manipulated samples (n = 30) used to fill the Hb bins. In addition, regression
analysis also showed equivalency with the reference method (Figs 2 and 3, S1 Fig).
Our stability results support using venous blood anticoagulated with EDTA within 24 hours
and capillary blood within 2 hours of draw. Our results showed more variation reflected as
larger mean %bias for AbsCD4 and %CD4 at about 24 hours post-draw (Table 8). Coinciden-
tally, we observed an increase in number of cartridge re-runs at about the 24-hour time point,
along with more errors (6B0F). However, the majority of the errors were resolved after re-run-
ning the cartridge.
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The BD FACSPresto reference interval results from the healthy cohort showed statistically
significant gender differences for each parameter (Table 12). Females had higher AbsCD4 and
%CD4, and males had higher Hb values. Statistically significant Hb gender differences are well
known and established [51]. However, it was surprising encountering similar gender differ-
ences in results for AbsCD4 and %CD4 in this cohort, since this was not observed in a previous
study [51] and further studies are necessary to established valid reference intervals for the FAC-
SPresto cartridge.
Precision studies of the BD FACSPresto Near-Patient CD4 Counter and the cartridge have
shown that the performance of the system is highly reproducible and robust (Tables 9 and 10)
for all three parameters in the different conditions tested. Regarding BD FACSPresto linearity,
total lymphocytes, AbsCD4, and Hb data has shown that the cartridge performance linear
ranges for these three parameters comply with the product claim ranges (Table 11), data to be
provided upon request. For the purpose of this evaluation, the algorithm embedded in the BD
FACSPresto collected and analyzed total lymphocyte and AbsCD4 count to report %CD4. The
software version used during data collection made available total lymph results for linearity
testing. Typically this information would not be available to the targeted end-user in resource-
limited setting health clinics, since calculation of the total lymphocytes has no clinical signifi-
cance for HIV/AIDS monitoring or treatment.
On the other hand, during our evaluation, the laboratory operators found that the BD FAC-
SPresto was easy to use with a friendly customer interface, and simple to navigate with support-
ing self-training materials for the different steps, from instrument QC, blood collection, sample
acquisition, to results handling.
The BD lancet used during the clinical evaluation has been marketed worldwide. This is a
safety engineered and reliable lancet. During capillary blood collection, there were a minimum
number of BD lancet failures (<1%) for the duration of the studies. In addition, capillary blood
was effectively and easily transferred directly onto the cartridge after a short training. The
simplicity of this procedure was reflected in our capillary blood results, which support the
AbsCD4, %CD4, and Hb equivalency with venous blood. Regarding sample throughput, the
cartridge incubation is staged outside the instrument on incubation tray(s) or in an incubation
workstation. The BD FACSPresto throughput is conservatively estimated to be 10 cartridges
per hour, with approximately 23 minutes from blood application to results. Despite the con-
straints of the clinical evaluation, the laboratory staff was able to run an average of 50 cartridges
in two instruments, including process controls, cartridge re-runs, and cartridge re-preparation,
suggesting that at the sites where the BD FACSPresto may be placed, it would be expected to
facilitate a rapid turnaround of the results.
Although performance characteristics should be a high priority with any new diagnostic
test, the impact of the BD FACSPresto Near-Patient CD4 Counter tests on treatment monitor-
ing and linkage to care should be considered, since this outweighs the effect of the tests' perfor-
mance characteristics within reasonable ranges. It has been shown that there is little added
value in long-term CD4 monitoring among virally suppressed patients, and stopping CD4
monitoring will have major cost savings [52–54]. Therefore, efforts are being made to discon-
tinue CD4 testing in situations where viral load testing is available and patients are virologically
suppressed.
However, CD4 cell counts, the prime indicator of HIV disease progression, can expedite the
process leading from HIV diagnosis to ART and improve clinical outcomes, since they still
continue to play an important part in initial decisions around ART initiation. To meet the 90-
90-90 targets [55], CD4 cell counts will continue to be used as a filter mechanism to prioritize
patients in need of treatment and clinical management. UNAIDS highlights that the current
viral load scale-up is at 25% and, it is expected to reach only 57% by 2019. Therefore, to meet
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the 2020 UNAIDS target of 90% virally suppressed patients, CD4 will continue to play a role
for countries lacking viral load testing capacity. This is recommended by WHO [56] for treat-
ment monitoring when viral load monitoring is limited and in cases in which the CD4 cell
count of a few patients might fail to increase despite virological suppression.
Near-patient and point-of-care CD4 tests can help more people reach care, since they offer
a way of providing portable capacity for rapid CD4 testing in settings where traditional CD4
testing using flow cytometry cannot be implemented. Therefore, availability of the BD FAC-
SPresto Near-Patient CD4 Counter in remote or resource-limited areas will aid in prompt clin-
ical management, especially for patients presenting late to care, those returning to care after a
period of treatment interruption, and those experiencing virological or clinical failure. Much of
this improvement is due to increased test completion and receipt of results.
Determination of CD4 cell count has an important role in decisions for screening and pro-
phylaxis for major opportunistic infections. There is a continuous need to monitor the CD4
count to determine whether patients require prophylaxis or not, and when to stop. Shubber
et al [57] have shown that baseline CD4 measurement might have a role in decisions around
use of nevirapine, in view of the potential increased risk of nevirapine-associated hypersensitiv-
ity reaction at increased CD4 cell counts. Attention must therefore remain focused on sustain-
ing improvements in any of the sequential steps of linkage after point-of-care CD4 testing. It is
important to identify cost-effective methods for immunologic staging that will expedite access
to care for the high-priority cases of the most immunosuppressed individuals in resource-lim-
ited settings.
In summary, the data suggests good agreement between the BD FACSPresto Near-Patient
CD4 Counter and laboratory-based CD4 and Hb testing, the BD FACSCalibur and the Sysmex
KX-21N. We find that devices such as the BD FACSPresto Near-Patient CD4 Counter for CD4
testing have the potential benefit of expanding timely access to testing, increasing timely initia-
tion of ART, providing the correct regimen, establishing a baseline enumeration for patients
beginning treatment, simplifying ART services at the primary care level, and reducing patient
loss to follow-up. This strategy can stop deaths and offer excellent value for immunologic
staging across a wide range of parameters in Kenya, as well as in a variety of resource-limited
settings. The results of the BD FACSPresto evaluation are compliant with the Transparent
Reporting of Evaluations with Non-randomized Design (S8 File). Further research is required
on the operational aspects of the BD FACSPresto Near-Patient CD4 Counter and other devices
defined as point-of-care CD4 testing services.
Limitations
Data from this study should be interpreted in light of a few important limitations. The study
was conducted in a single research facility, and while this facility is broadly representative of
HIV research facilities in this setting, the results may not be generalizable to other facilities
within the country. The CD4 tests were done by laboratory staff. CD4 monitoring level 2 to 4
health facilities will require strong capacity building among staff and constant supervision to
ensure high quality sample collection and testing. There may be divergence in agreement
between BD FACSPresto instruments and operators, and this warrants further consideration.
Conclusions
The BD FACSPresto Near-Patient CD4 Counter is a robust, reliable, and easy to use system
that provides accurate, robust, precise and linear clinical results for capillary or venous samples.
The BD FACSPresto is a suitable alternative requiring short user training for optimally
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generating CD4 and Hb integrated results in health care facilities in resource-limited settings.
This product was CE Marked (IVD Directive 98/79/EC) and WHO prequalified (2014).
Supporting Information
S1 Fig. AbsCD4, %CD4 and Hb Deming Regression Results in Venous and Capillary
Blood. Regression analysis with Deming fit of venous and capillary blood samples. In the left
side shows results from venous blood (A, C and E), and the right side illustrates capillary blood
(B, D and F) plots. The plots at the top depict the AbsCD4 results (A and B); %CD4 results are
shown in the middle(C and D), and the Hb plots are at the bottom (E and F) with R2, slope,
and y-intercept data. The BD FACSCalibur results are represented in the x-axis and the BD
FACSPresto results in the y-axis.
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